• A nurse in black scrubs talks to a patient sitting behind a screen at an improvised dockside clinic

    Docside Clinic brings primary care to underserved maritime community

    University of Texas Medical Branch researcher Dr. Shannon Guillot-Wright was recently awarded a $660,000 grant from the Centers for Disease Control to fund a five-year research project to address health disparities for commercial fishermen.

  • UTMB Awarded Project Agreement Up to $24.7M from the U.S. Department of Defense to Develop mRNA Vaccines to Prevent Biological Threat Agent Diseases

    UTMB has been awarded an agreement up to nearly $25 million from the U.S. Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) (within the Administration for Strategic Preparedness and Response (ASPR)), for their efforts in the collaborative development of vaccines to protect against infection by Ebola (EBOV), Sudan (SUDV), Marburg (MARV), and Lassa (LASV) viruses. This project award was executed via Other Transaction Authority (OTA) to UTMB through the Medical CBRN Defense Consortium (MCDC).

  • Researchers Develop Machine Learning Methods for Improving Patient Care through Disease Subtypes

    To help health care professionals find the connections between health conditions, risk and treatment plans, researchers at the University of Texas Medical Branch developed machine learning methods that can automatically find conditions that frequently go together in national level data, and used them to predict the risk of a patient in the clinic, and for designing targeted treatments.

  • A blue image of letters and test tubes

    UTMB and HDT Bio awarded prototype project funding worth up to $87.4M from the U.S. government to develop saRNA vaccine technology

    The University of Texas Medical Branch (UTMB) has been awarded a project agreement worth up to $87.4 million by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR), through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA), for the development of a vaccine technology against advanced and emerging viral threats. Two deadly viruses of significance to military personnel will be targeted for vaccine protection. These are Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV).